Literature DB >> 19802428

[Statement about the medical and surgical treatment of overweight and obesity].

Fernando Carrasco N1, Mónica Manrique, María Pía de la Maza, Manuel Moreno, Cecilia Albala, Jaime García, Jaime Díaz, Claudio Liberman.   

Abstract

This is an updated review of the available treatments for obesity, which can be used when lifestyles modifications fail. Using the available information and the experience of the members of this advisory group, a recommendation is given about the most useful treatments, according to the severity of obesity and its complications. With regards to pharmacological treatments, only sibutramine and orlistat are approved on a worldwide basis for the treatment of obesity. These medications achieve a 10% higher weight reduction than lifestyles modification. A third medication, rimonobant, is also more effective than lifestyles modifications, but it was withdrawn due to psychological safety issues. The indications for surgical treatment and a brief description of the available techniques, success rates and complications are outlined. Finally, the need to have followed up protocols for patients and the formation of multidisciplinary treatment teams is underscored.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19802428     DOI: /S0034-98872009000700017

Source DB:  PubMed          Journal:  Rev Med Chil        ISSN: 0034-9887            Impact factor:   0.553


  1 in total

1.  Macrocytic anemia and thrombocytopenia induced by orlistat.

Authors:  David Palacios-Martinez; Juan Carlos Garcia-Alvarez; Nieves Montero-Santamaria; Olga Patricia Villar-Ruiz; Antonio Ruiz-Garcia; Raquel Asuncion Diaz-Alonso
Journal:  Int J Endocrinol Metab       Date:  2013-10-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.